Cardiovascular Drugs and Therapy

, Volume 19, Issue 4, pp 291–299

Pharmacotherapy of Acute Coronary Syndromes: Medical Economics with an Emphasis on Clopidogrel

  • Matthias Bramkamp
  • Konstantin J. Dedes
  • Thomas D. Szucs

DOI: 10.1007/s10557-005-3694-7

Cite this article as:
Bramkamp, M., Dedes, K.J. & Szucs, T.D. Cardiovasc Drugs Ther (2005) 19: 291. doi:10.1007/s10557-005-3694-7


Acute coronary syndromes account worldwide for a significant burden of hospital- and societal costs. Pharmacotherapy of acute coronary syndromes consists of a combined antithrombotic therapy. Remarkable therapeutic advances have been made with the introduction of glycoprotein IIb/IIIa receptor inhibitors, low molecular weight heparins and thienopyridines, such as clopidogrel. Based on positive clinical data of large randomized trials numerous cost studies have been undertaken to analyse the cost-effectiveness of these new drugs. Most of them are showing an acceptable level of cost-effectiveness for the new treatments. Taking all available cost-studies into account, we conclude that new antithrombotic treatments are cost-effective as long as their use is limited to selected patient populations.

Key Words

acute coronary syndrome cost-effectiveness clopidogrel acetyl salicylic acid 

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Matthias Bramkamp
    • 1
  • Konstantin J. Dedes
    • 2
  • Thomas D. Szucs
    • 3
  1. 1.Department of Internal Medicine, Medical PoliclinicUniversity HospitalZurichSwitzerland
  2. 2.Department of GynecologyUniversity Hospital ZurichSwitzerland
  3. 3.Institute for Social and Preventive MedicineUniversity of ZurichZurichSwitzerland
  4. 4.Institute for Social and Preventive MedicineUniversity of ZurichZurichSwitzerland

Personalised recommendations